Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.54 |
| ▸ | AGXT | P21549 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brocresine SCHEMBL29466825 | 1.00 | IDO1 (0.54) | IDO1AGXTCA12CA1CA2 | |
| Brocresine SCHEMBL10914167 | 0.91 | IDO1 (0.46) | IDO1AGXTCA12CA1CA2 | |
| SCHEMBL8988644 | 0.81 | IDO1 (0.60) | IDO1CA1CA2CYP3A4 | |
| SCHEMBL31617756 | 0.80 | PTPN1 (0.41) | CA2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9567644 | 0.79 | IDO1 (0.61) | IDO1AGXTCA1CA2CYP3A4 | |
| SCHEMBL13163675 | 0.77 | ABAT (0.46) | CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL22418989 | 0.75 | MAPT (0.45) | CA12CA1CA2CA9 | |
| SCHEMBL31617710 | 0.74 | APP (0.38) | — | |
| SCHEMBL27721894 | 0.74 | CYP3A4 (0.51) | CA2CYP3A4 | |
| SCHEMBL21978741 | 0.74 | USP14 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230043198-A1 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | YALE UNIVERSITY (US) | 2023-02-09 | — | — | US | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3893941-A1 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | Yale University (US) | 2021-10-20 | — | — | EP | claimed |
| WO-2020123376-A1 | MICROBIOTA METABOLITES THAT SHAPE HOST PHYSIOLOGY | YALE UNIVERSITY (US) | 2020-06-18 | — | — | WO | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-4411899-A | Substituted derivatives of amino alkane diols as gastric secretion inhibitors | MERCK & CO., INC. (US) | 1983-10-25 | — | — | US | claimed |
| EP-0082376-A2 | Substituted derivatives of amino alkane diols as gastric secretion inhibitors | MERCK & CO. INC. (US) | 1983-06-29 | — | — | EP | claimed |
| EP-0073971-A1 | Thiadiazole oxides as gastric antisecretory agents | MERCK & CO. INC. (US) | 1983-03-16 | — | — | EP | claimed |
| US-4288542-A | METHYLATION WITH TRANSFERASE | THE UPJOHN COMPANY (US) | 1981-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | IDO1 1826/4885AGXT 2976/4885CA12 1448/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | IDO1 552/4885AGXT 2026/4885CA12 1083/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | IDO1 3864/4885AGXT 423/4885CA12 7/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | IDO1 3864/4885AGXT 423/4885CA12 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.